

Teva Specialty Product Pipeline

November 2018

Phase 2	Phase 3	Registration	Recent Approvals
Fremanezumab (anti-CGRP) <i>Post-Traumatic Headache</i>	Fremanezumab (anti-CGRP) <i>Cluster Headache</i>	Fremanezumab (anti-CGRP) <i>Migraine</i> (EU and Selected International Markets)	AJOVY™ (fremanezumab-vfrm) injection (US)
Fasinumab ¹ <i>Chronic Lower Back Pain</i>	Fasinumab ¹ <i>Osteoarthritis pain</i>	Albuterol eMDPI E-connectivity (US)	TRUXIMA® ² (rituximab-abbs) injection (US)
	Deutetrabenazine, SD-809 <i>Tourette Syndrome (US)</i>	CT-P6 ² (<i>trastuzumab proposed biosimilar</i>)	AZILECT® ⁴ (rasagiline) (Japan)
	TV-46000 (risperidone LAI) <i>Schizophrenia (US)</i>	Bendamustine HCl ³ <i>CLL and NHL</i> (Selected International Markets)	TRISENOX® (arsenic trioxide) injection (US)

10 programs in Phase 2 through Registration

■ Migraine & Pain	5
■ Neurology & Neuropsychiatry	2
■ Respiratory	1
■ Biosimilars	1
■ Other TA	1

Note: Pipeline is current as of November 2018

¹In partnership with Regeneron

²In partnership with Celltrion

³In partnership with Eagle Pharmaceuticals

⁴Out-licensed to Takeda